BrightPath Biotherapeutics and Artisan Bio have signed a research and licensing agreement to expedite the former’s allogeneic next-generation invariant natural killer T (iNKT) cell therapies to clinic.

BrightPath will obtain non-exclusive rights to the STAR-CRISPR editing platform of Artisan Bio for accelerating the development of BrightPath’s iNKT cells.

BrightPath Biotherapeutics CEO Kenichi Nagai stated: “This collaboration with Artisan provides us with the potential to create highly engineered allogeneic iNKT cellular therapy programmes for a range of indications, including solid tumours.

“Artisan’s STAR-CRISPR system, and their leading editing efficiencies in iPSC cells, will enable our iNKT cell therapies to solve the persistence and efficacy problems faced by first-generation allogeneic CAR-T programmes.”

Artisan will receive an upfront payment and research milestone payments, along with licence fees and development milestones from BrightPath.

The company will also receive net sales milestones and royalties on future products.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Artisan Bio CEO Ryan Gill stated: “We are excited for the BrightPath collaboration and the development of highly engineered iPS cells for cell therapy.

“The BrightPath products will build upon our leading STAR-CRISPR platform, our highly optimised guides for allogeneic and proprietary target genes, and our rigorous off-target safety profiling.”

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.